Human prion diseases: Molecular and clinical aspects

Archives of Neurology

Volumn 62, Issue 4, 2005, Pages 545-552

  Glatzel, Markus ^a   Stoeck, Katharina ^a   Seeger, Harald ^a   Lührs, Thorsten ^b   Aguzzi, Adriano ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b SALK INSTITUTE FOR BIOLOGICAL STUDIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NUCLEIC ACID; PRION PROTEIN;

CREUTZFELDT JAKOB DISEASE; EVIDENCE BASED MEDICINE; HUMAN; PHENOTYPE; PRION; PRION DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; REVIEW; VIRUS REPLICATION;

ANIMALS; BRAIN; CATTLE; CREUTZFELDT-JAKOB SYNDROME; ENCEPHALOPATHY, BOVINE SPONGIFORM; HUMANS; PRION DISEASES; PRPC PROTEINS; PRPSC PROTEINS;

EID: 16844370011     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.62.4.545     Document Type: Review

References (67)

1. Aguzzi A, Montrasio F, Kaeser PS. Prions: health scare and biological challenge. Nat Rev Mol Cell Biol. 2001;2:118-126.
2. Aguzzi A, Polymenidou M. Mammalian prion biology, one century of evolving concepts. Cell. 2004;116:313-327.
3. Aguzzi A, Haass C. Games played by rogue proteins in prion disorders and Alzheimer's disease. Science. 2003;302:814-818.
4. Budka H, Aguzzi A, Brown P, et al. Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol. 1995;5:459-466.
5. Legname G, Baskakov IV, Nguyen HO, et al. Synthetic mammalian prions. Science. 2004;305:673-676.
6. Glatzel M, Ott PM, Lindner T, et al. Human prion diseases: epidemiology and integrated risk assessment. Lancet Neurol. 2003;2:757-763.
7. Brandel JP, Delasnerie-Laupretre N, Laplanche JL, Hauw JJ, Alperovitch A. Diagnosis of Creutzfeldt-Jakob disease: effect of clinical criteria on incidence estimates. Neurology. 2000;54:1095-1099.
8. Glatzel M, Rogivue C, Ghani A, Streffer JR, Amsler L, Aguzzi A. Incidence of Creutzfeldt-Jakob disease in Switzerland. Lancet. 2002;360:139-141.
9. Hsiao K, Baker HF, Crow TJ, et al. Linkage of a prion protein missense variant to Gerstmann-Straussler syndrome. Nature. 1989;338:342-345.
10. Brown P, Preece M, Brandel JP, et al. Iatrogenic Creutzfeldt-Jakob disease at the millennium. Neurology. 2000;55:1075-1081.
11. Hill AF, Desbruslais M, Joiner S, et al. The same prion strain causes vCJD and BSE. Nature. 1997;389:448-450.
12. Bruce ME, Will RG, Ironside JW, et al. Transmissions to mice indicate that "new variant" CJD is caused by the BSE agent. Nature. 1997;389:498-501.
13. Aguzzi A, Weissmann C. Spongiform encephalopathies: a suspicious signature. Nature. 1996;383:666-667.
14. Kirkwood JK, Cunningham AA. Epidemiological observations on spongiform encephalopathies in captive wild animals in the British Isles. Vet Rec. 1994;135:296-303.
15. Palmer MS, Dryden AJ, Hughes JT, Collinge J. Homozygous prion protein genotype predisposes to sporadic Creutzfeldt-Jakob disease. Nature. 1991;352:340-342.
16. Goldmann W, Hunter N, Smith G, Foster J, Hope J. PrP genotype and agent effects in scrapie: change in allelic interaction with different isolates of agent in sheep, a natural host of scrapie. J Gen Virol. 1994;75:989-995.
17. Drisaldi B, Stewart RS, Adles C, et al. Mutant PrP is delayed in its exit from the endoplasmic reticulum, but neither wild-type nor mutant PrP undergoes retrotranslocation prior to proteasomal degradation. J Biol Chem. 2003;278:21732-21743.
18. Naslavsky N, Stein R, Yanai A, Friedlander G, Taraboulos A. Characterization of detergent-insoluble complexes containing the cellular prion protein and its scrapie isoform. J Biol Chem. 1997;272:6324-6331.
19. Bueler H, Aguzzi A, Sailer A, et al. Mice devoid of PrP are resistant to scrapie. Cell. 1993;73:1339-1347.
20. Solforosi L, Criado JR, McGavern DB, et al. Cross-linking cellular prion protein triggers neuronal apoptosis in vivo. Science. 2004;303:1514-1516.
21. Glockshuber R, Hornemann S, Billeter M, Riek R, Wider G, Wuthrich K. Prion protein structural features indicate possible relations to signal peptidases. FEBS Lett. 1998;426:291-296.
22. Brown DR, Wong BS, Hafiz F, Clive C, Haswell SJ, Jones IM. Normal prion protein has an activity like that of superoxide dismutase. Biochem J. 1999;344:1-5.
23. Hutter G, Heppner FL, Aguzzi A. No superoxide dismutase activity of cellular prion protein in vivo. Biol Chem. 2003;384:1279-1285.
24. Kurschner C, Morgan JI, Yehiely F, et al. The cellular prion protein (PrP) selectively binds to Bcl-2 in the yeast two-hybrid system: identification of candidate proteins binding to prion protein. Brain Res Mol Brain Res. 1995;30:165-168.
25. Gorodinsky A, Harris DA. Glycolipid-anchored proteins in neuroblastoma cells form detergent-resistant complexes without caveolin. J Cell Biol. 1995;129:619-627.
26. Rieger R, Edenhofer F, Lasmezas CI, Weiss S. The human 37-kDa laminin receptor precursor interacts with the prion protein in eukaryotic cells. Nat Med. 1997;3:1383-1388.
27. Fischer MB, Roeckl C, Parizek P, Schwarz HP, Aguzzi A. Binding of disease-associated prion protein to plasminogen. Nature. 2000;408:479-483.
28. Schmitt-Ulms G, Legname G, Baldwin MA, et al. Binding of neural cell adhesion molecules (N-CAMs) to the cellular prion protein. J Mol Biol. 2001;314:1209-1225.
29. Watarai M, Kim S, Erdenebaatar J, et al. Cellular prion protein promotes Brucella infection into macrophages. J Exp Med. 2003;198:5-17.
30. Aguzzi A, Hardt WD. Dangerous liaisons between a microbe and the prion protein. J Exp Med. 2003;198:1-4.
31. Alper T. The scrapie enigma: insights from radiation experiments. Radiat Res. 1993;135:283-292.
32. Griffith JS. Self-replication and scrapie. Nature. 1967;215:1043-1044.
33. McKinley MP, Bolton DC, Prusiner SB. A protease-resistant protein is a structural component of the scrapie prion. Cell. 1983;35:57-62.
34. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216:136-144.
35. Aguzzi A, Weissmann C. Prion research: the next frontiers. Nature. 1997;389:795-798.
36. Prusiner SB. Prions. Proc Natl Acad Sci USA. 1998;95:13363-13383.
37. Jarrett JT, Lansbury PT Jr. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell. 1993;73:1055-1058.
38. King CY, Diaz-Avalos R. Protein-only transmission of three yeast prion strains. Nature. 2004;428:319-323.
39. Tanaka M, Chien P, Naber N, Cooke R, Weissman JS. Conformational variations in an infectious protein determine prion strain differences. Nature. 2004;428:323-328.
40. Collins SJ, Lawson VA, Masters PC. Transmissible spongiform encephalopathies. Lancet. 2004;363:51-61.
41. Zerr I, Schulz-Schaeffer WJ, Giese A, et al. Current clinical diagnosis in Creutzfeldt-Jakob disease: identification of uncommon variants. Ann Neurol. 2000;48:323-329.
42. Tribl GG, Strasser G, Zeitlhofer J, et al. Sequential MRI in a case of Creutzfeldt-Jakob disease. Neuroradiology. 2002;44:223-226.
43. Zeidler M, Sellar RJ, Collie DA, et al. The pulvinar sign on magnetic resonance imaging in variant Creutzfeldt-Jakob disease. Lancet. 2000;355:1412-1418.
44. Zeidler M, Collie DA, Macleod MA, Sellar RJ, Knight R. FLAIR MRI in sporadic Creutzfeldt-Jakob disease. Neurology. 2001;56:282.
45. Hill AF, Butterworth RJ, Joiner S, et al. Investigation of variant Creutzfeldt-Jakob disease and other human prion diseases with tonsil biopsy samples. Lancet. 1999;353:183-189.
46. Zanusso G, Ferrari S, Cardone F, et al. Detection of pathologic prion protein in the olfactory epithelium in sporadic Creutzfeldt-Jakob disease. N Engl J Med. 2003;348:711-719.
47. Glatzel M, Abela E, Maissen M, Aguzzi A. Extraneural pathologic prion protein in sporadic Creutzfeldt-Jakob disease. N Engl J Med. 2003;349:1812-1820.
48. Windl O, Giese A, Schulz-Schaeffer W, et al. Molecular genetics of human prion diseases in Germany. Hum Genet. 1999;105:244-252.
49. Alperovitch A, Zerr I, Pocchiari M, et al. Codon 129 prion protein genotype and sporadic Creutzfeldt-Jakob disease. Lancet. 1999;353:1673-1674.
50. Parchi P, Castellani R, Capellari S, et al. Molecular basis of phenotypic variability in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 1996;39:767-778.
51. Hill AF, Joiner S, Wadsworth JD, et al. Molecular classification of sporadic Creutzfeldt-Jakob disease. Brain. 2003;126:1333-1346.
52. Parchi P, Giese A, Capellari S, et al. Classification of sporadic Creutzfeldt-Jakob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46:224-233.
53. Notari S, Capellari S, Giese A, et al. Effects of different experimental conditions on the PrPSc core generated by protease digestion: implications for strain typing and molecular classification of CJD. J Biol Cnem. 2004;279:16797-16804.
54. Aguzzi A. Understanding the diversity of prions. Nat Cell Biol. 2004;6:290-292.
55. Gambetti P, Kong Q, Zou W, Parchi P, Chen SG. Sporadic and familial CJD: classification and characterisation. Br Med Bull. 2003;66:213-239.
56. Harder A, Jendroska K, Kreuz F, et al. Novel twelve-generation kindred of fatal familial insomnia from Germany representing the entire spectrum of disease expression. Am J Med Genet. 1999;87:311-316.
57. Ghetti B, Dlouhy SR, Giaccone G, et al. Gerstmann-Straussler-Scheinker disease and the Indiana kindred. Brain Pathol. 1995;5:61-75.
58. Padovani A, D'Alessandro M, Parchi P, et al. Fatal familial insomnia in a new Italian kindred. Neurology. 1998;51:1491-1494.
59. Will RG, Ironside JW, Zeidler M, et al. A new variant of Creutzfeldt-Jakob disease in the UK. Lancet. 1996;347:921-925.
60. Aguzzi A. Between cows and monkeys. Nature. 1996;381:734.
61. Valleron AJ, Boelle PY, Will R, Cesbron JY. Estimation of epidemic size and incubation time based on age characteristics of vCJD in the United Kingdom. Science. 2001;294:1726-1728.
62. Aguzzi A, Glatzel M, Montrasio F, Prinz M, Heppner FL. Interventional strategies against prion diseases. Nat Rev Neurosci. 2001;2:745-749.
63. Montrasio F, Frigg R, Glatzel M, et al. Impaired prion replication in spleens of mice lacking functional follicular dendritic cells. Science. 2000;288:1257-1259.
64. Glatzel M, Heppner FL, Albers KM, Aguzzi A. Sympathetic innervation of lymphoreticular organs is rate limiting for prion neuroinvasion. Neuron. 2001;31:25-34.
65. Meier P, Genoud N, Prinz M, et al. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease. Cell. 2003;113:49-60.
66. Caughey B, Raymond LD, Raymond GJ, Maxson L, Silveira J, Baron GS. Inhibition of protease-resistant prion protein accumulation in vitro by curcumin. J Virol. 2003;77:5499-5502.
67. Collins SJ, Lewis V, Brazier M, Hill AF, Fletcher A, Masters CL. Quinacrine does not prolong survival in a murine Creutzfeldt-Jakob disease model. Ann Neurol. 2002;52:503-506.